MedTrace Logo

Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections

NCT02052388 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 215

Last updated 2018-09-26

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and efficacy of three different dosing regimens of brilacidin compared to daptomycin for the treatment of serious skin infections. This study will aid in selecting the appropriate dose of brilacidin for later stage studies.

Conditions

Interventions

DRUG

Daptomycin

Active Comparator

DRUG

Brilacidin

Experimental Drug

Sponsors & Collaborators

  • Cellceutix Corporation

    lead INDUSTRY

Principal Investigators

  • William O'Riordan, MD · eStudy SIte

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02052388 on ClinicalTrials.gov